CTEV
ClaritevDNYSE / Health Care Equipment & Services
Last Price
At close
2026-06-02
Current thesis
Q1 showed continued revenue growth and solid adjusted EBITDA, while PHCS Novera gives Claritev a tangible 2026 product-rollout path. If management can keep growth moving and convert the launch into commercial wins while holding covenant compliance and improving cash flow, the equity can rerate from a depressed leverage discount.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +3.7.
What can break
Gross debt remains high at roughly $4.6 billion, so interest burden and refinancing sensitivity still matter.
Momentum
59
Value
52
Sentiment
26
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $20.50 · Bull $31.00 · Bear $9.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $43.60
Why
Momentum59 · Δ7d +3.7
Value52 · Δ7d -0.1
Sentiment26 · Δ7d -15.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
59
34% active weight
Current posture
7d trendImproving
Δ7d
+3.7
Δ21d
-30.1
Value
52
32% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.4
Sentiment
26
33% active weight
Current posture
7d trendSoftening
Δ7d
-15.4
Δ21d
-8.6
Why this grade
Composite grade D. Momentum 59.4 / Value 51.5 / Sentiment 25.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$460.12M
Beta
0.53
Shares Out
16.53M
P/E (TTM) · Derived
-1.6
P/S (TTM)
0.51
P/FCF (TTM) · Derived
-4.05
Rev YoY
+6.7%
EPS YoY
+82.5%
Gross Margin
+74.7%
Op Margin
-8.1%
Net Debt
$4.51B
Current Ratio
1.21
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology